Known targets — ChEMBL curated mechanism
EGFREPHA1EPHA10EPHA2EPHA3EPHA4EPHA5EPHA6EPHA7EPHA8EPHB1EPHB2EPHB3EPHB4EPHB6ERBB2ERBB3ERBB4FLT1FLT4KDRPTK6RETSRCTEK
The experimentally established mechanism targets of Vandetanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 16/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 13/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 11/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 11/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 3/20 | 1.00 |
| ▸ | EPHA2 known ✓ | P29317 | 3/20 | 1.00 |
| ▸ | EPHB4 known ✓ | P54760 | 3/20 | 1.00 |
| ▸ | TEK known ✓ | Q02763 | 2/20 | 1.00 |
| ▸ | EPHB6 known ✓ | O15197 | 1/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 1.00 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 1.00 |
| ▸ | EPHA1 known ✓ | P21709 | 1/20 | 1.00 |
| ▸ | ERBB3 known ✓ | P21860 | 1/20 | 1.00 |
| ▸ | EPHA3 known ✓ | P29320 | 1/20 | 1.00 |
| ▸ | EPHA8 known ✓ | P29322 | 1/20 | 1.00 |
| ▸ | EPHB2 known ✓ | P29323 | 1/20 | 1.00 |
| ▸ | EPHA5 known ✓ | P54756 | 1/20 | 1.00 |
| ▸ | EPHB1 known ✓ | P54762 | 1/20 | 1.00 |
| ▸ | EPHA4 known ✓ | P54764 | 1/20 | 1.00 |
| ▸ | PTK6 known ✓ | Q13882 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vandetanib SCHEMBL28224661 | 1.00 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL29352879 | 1.00 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL1614458 | 0.99 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL4637084 | 0.99 | EGFR (0.98) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL1783178 | 0.94 | EGFR (0.89) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL4544070 | 0.93 | EGFR (0.87) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL1614619 | 0.93 | EGFR (0.86) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL26359052 | 0.92 | EGFR (0.85) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL12534441 | 0.92 | EGFR (0.85) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL27218180 | 0.91 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 38629 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746970-A1 | EGFR ANTAGONISTS FOR THE TREATMENT OF DISEASES INVOLVING UNWANTED MIGRATION, PROLIFERATION, AND/OR METAPLASIA OF RETINAL PIGMENT EPITHELIUM (RPE) CELLS | Jonas, Jost B. (DE) | 2026-05-27 | — | — | EP | claimed |
| EP-4747285-A1 | MONOCLONAL ANTIBODIES AGAINST PCDH7 FOR LUNG CANCER THERAPY | The Board of Regents of the University of Texas System (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026103823-A1 | COMBINATION OF RAS INHIBITOR AND EGFR INHIBITOR AND USE THEREOF | 广州嘉越医药科技有限公司 | 2026-05-21 | — | — | WO | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260137638-A1 | STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER | TYARDI OPERATING CO INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-1622619-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | Boehringer Ingelheim International GmbH (DE) | 2006-02-08 | — | — | EP | claimed |
| US-20050281761-A1 | Methods of preventing UVB-induced skin damage | DETMAR MICHAEL | 2005-12-22 | — | — | US | claimed |
| WO-2005097187-A2 | METHODS OF PREVENTING UVB-INDUCED SKIN DAMAGE | THE GENERAL HOSPITAL CORPORATION (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050222183-A1 | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | claimed |
| EP-1530466-A2 | USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES | Boehringer Ingelheim Pharma KG (DE) | 2005-05-18 | — | — | EP | claimed |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | claimed |
| WO-2004096224-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-11 | — | — | WO | claimed |
| US-20040204458-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-14 | — | — | US | claimed |
| WO-2004017948-A2 | USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | WO | claimed |
| US-20030144298-A1 | Using a combination of an angiogenisis inhibitor and a hypotensive agent for use in treating diseases associated with angiogenesis; an endothelial growth factor receptor tyrosine kinase inhibitor; antidiabetic, -arthritis agents | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | claimed |